What Tederox® is?
Tederox is a cancer medicine that contains the active substance trastuzumab deruxtecan and commonly named as T-DXd. It offers a more targeted and effective approach to specific cancers treatment, that have the protein HER2 on their surface (HER2-positive).
What Tederox® is used for?
HER2-positive breast cancer, HER2-low breast cancer, HER2-mutant non-small cell lung cancer, HER2-positive stomach cancer and some other HER-2 positive cancers.
What is the mechanism of action of Tederox®?
One part of the medicine is a monoclonal antibody that attaches specifically to cells that have the protein HER2 on their surface (HER2-positive), as some cancer cells do. The other active part of Tederox is DXd, a substance that can kill cancer cells. Once the medicine has attached to HER2-positive cancer cells, the DXd enters the cells and kills them.
Considerations:
  • If you are allergic to trastuzumab deruxtecan or any of the other ingredients of this medicine You must not be given Tederox®.
  • Tederox® is not recommended for anyone under the age of 18 years.
  • Tederox® is not recommended during pregnancy because this medicine may harm the unborn baby. You should not breast-feed during treatment with Tederox® and for at least 7 months after your last dose. Use effective contraception (birth control) to avoid becoming pregnant while being treated with Tederox®. Women taking Tederox® should continue contraception for at least 7 months after the last dose of Tederox®. Men taking Tederox® whose partner may become pregnant should use effective contraception: during treatment and for at least 4 months after the last dose of Tederox®.
  • Store in a refrigerator (2 °C – 8 °C). Do not freeze. If not used immediately after reconstitution, store the reconstituted vials in a refrigerator at 2 ° C to 8 ° C for up to 24 hours from the time of reconstitution, protected from light. Do not freeze. The diluted medicine, could be stored at room temperature up to 5 hours including preparation and infusion or in a refrigerator at 2 ° C to 8 ° C for up to 24 hours, protected from light.
  • Administered dose would be calculated based on patients’ weight and ranged f 5.4-6.4 mg/kg in different cancers.
  • The initial dose should be administered as a 90-minute intravenous infusion. If the prior infusion was well tolerated, subsequent doses of medication may be administered as 30-minute infusions. Do not administer as an intravenous push or bolus.
  • Like all medicines, this medicine can cause side effects, although not everybody gets them. Speak with your doctor immediately if you notice any of the following symptoms:
  • cough, shortness of breath, fever, or other new or worsening breathing problems chills, fever, sores in your mouth, stomach pain or pain when urinating tiredness, swelling of ankles or legs, irregular heartbeat, sudden weight gain,

Don’t hesitate to get in touch with us through the link below to submit an adverse event report from taking this medicine.

Adverse Event Report